Saw this question on another board. I'm confuse
Post# of 30027
Posted On: 11/06/2015 10:33:03 PM
Saw this question on another board.
I'm confused. Is AMBS a a regenerative or a neurologic company?
We'll you see, MANF actually is both regenerative and neurologic but has much more potential beyond the brain. The "golden goose" has always been MANF. Selling non-MANF assets to get there has been the strategy from early on.
I also forgot to add ESS
Looks like nothing is going to happen until the JP Morgan conference? Does it make sense to buy a week before?
- Take a look at the last column of the pipeline slide. Note that is only for ESS and Elto. That's a lot of milestones some of which can happen in Nov and Dec.
- Add to that and update on Lympro - CTE and possible PET
- An update on MSPrecse (i.e. Largest Diagnostic Study Ever)
- The final Dx deal may be annouced at the JP conference but updates, LOI, etc may come before - "We remain on track to transact on the diagnostics division in the fourth quarter and will provide updates on this as progress is made."
- MANF - We know there is news coming here. For example Dr. Urano has said as much. They could also announce a MANF partner in the next few weeks or next few years. No way of telling.
- Looks like ESS is planned to start in Dec. based on the latest update on the U.S. National Institutes of Health site, but that could change obviously.
I'm confused. Is AMBS a a regenerative or a neurologic company?
We'll you see, MANF actually is both regenerative and neurologic but has much more potential beyond the brain. The "golden goose" has always been MANF. Selling non-MANF assets to get there has been the strategy from early on.
Quote:http://wolframsyndrome.dom.wustl.edu/progress/
The development of regenerative therapy using a biologic called MANF is ongoing. We are getting positive preclinical data.
I also forgot to add ESS
Looks like nothing is going to happen until the JP Morgan conference? Does it make sense to buy a week before?
- Take a look at the last column of the pipeline slide. Note that is only for ESS and Elto. That's a lot of milestones some of which can happen in Nov and Dec.
- Add to that and update on Lympro - CTE and possible PET
- An update on MSPrecse (i.e. Largest Diagnostic Study Ever)
- The final Dx deal may be annouced at the JP conference but updates, LOI, etc may come before - "We remain on track to transact on the diagnostics division in the fourth quarter and will provide updates on this as progress is made."
- MANF - We know there is news coming here. For example Dr. Urano has said as much. They could also announce a MANF partner in the next few weeks or next few years. No way of telling.
- Looks like ESS is planned to start in Dec. based on the latest update on the U.S. National Institutes of Health site, but that could change obviously.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼